Via EFS Filed: March 20, 2008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: BERGMANN et al. Attorney Dkt. No.: 2582.022
Serial No.: 09/889,094 Examiner: Michael D. Pak

Filed: October 19, 2001 Group Art Unit: 1646

Title: USE OF BLOCKING ANTI-TSH-RECEPTOR-ANTIBODIES IN THE THERAPY OF HYPERTHYREOSES AND MONOCLONAL ANTIBODIES

FOR USE OF THIS TYPE

Confirmation No.: 7928

To: Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicants hereby make of record in the instant application the documents listed on the attached Form 1449.

This Information Disclosure Statement is filed concurrently with a Request for Continued Examination, to remove the finality of an Office Action. Accordingly, no fee for the IDS is believed due. This information is being cited out of an abundance of caution in view of the decisions in Akron Polymer Container v. Exxel Container, 148 F.3d 1380 (Fed. Cir. 1998) and McKesson Information Solutions v. Bridge Medical, Inc., 487 F.3d 897 (Fed. Cir. 2007).

Applicants respectfully request that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning patentability of the present claims, and initial, sign, and date the enclosed Form 1449, and return a copy of the signed Form 1449 with the next U.S. Patent and Trademark communication to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By citing these references, Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b); and (3) the information cited is, or is considered to be, in fact, prior art as defined by 35 U.S.C. § 102.

Notwithstanding any statements by Applicants, or treatment of this cited information by this or another Patent Office, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited references. An early and favorable action is hereby requested.

The Commissioner is hereby authorized to charge payment of any fees that may be required, or credit any overpayment of same, to Deposit Account No. 08-1935, Reference No. 2582 022

Respectfully submitted,

Smith Dias Attorney for Applicant

Registration No. 41,707

Dated: March 20, 2008

HESLIN ROTHENBERG FARLEY & MESITI P.C.

5 Columbia Circle

Albany, New York 12203

Phone: 518-452-5600 Fax: 518-452-5579